KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Non-Current Assets (2017 - 2025)

Bionano Genomics' Non-Current Assets history spans 7 years, with the latest figure at $30.3 million for Q3 2025.

  • For Q3 2025, Non-Current Assets fell 25.06% year-over-year to $30.3 million; the TTM value through Sep 2025 reached $134.3 million, down 47.52%, while the annual FY2024 figure was $37.2 million, 49.95% down from the prior year.
  • Non-Current Assets for Q3 2025 was $30.3 million at Bionano Genomics, down from $33.3 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $150.2 million in Q4 2022 and bottomed at $14.6 million in Q1 2021.
  • The 5-year median for Non-Current Assets is $72.4 million (2024), against an average of $72.9 million.
  • The largest annual shift saw Non-Current Assets surged 666.26% in 2021 before it plummeted 53.77% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $104.7 million in 2021, then soared by 43.48% to $150.2 million in 2022, then tumbled by 50.54% to $74.3 million in 2023, then crashed by 49.95% to $37.2 million in 2024, then fell by 18.61% to $30.3 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Non-Current Assets are $30.3 million (Q3 2025), $33.3 million (Q2 2025), and $33.5 million (Q1 2025).